China Biopharma said that its partner, Soonfast Pharmaceutical, completed a trial production run of its topical antiviral. In June, China Biopharma acquired the ex-China rights to the product, which treats herpes simplex virus (HSV) and human papillomavirus (HPV). The product has been approved for use in China, and will launch in November, now that commercial-level manufacturing has begun. More details...

Stock Symbol: (OTCBB: CBPC)